Compare iShares MSCI Hong Kong ETF (EWH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.09 (market cap $1.16B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 12.4× iShares MSCI Hong Kong ETF's market cap, and iShares MSCI Hong Kong ETF is more actively traded (3,176,523 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWH | NBIX | |
|---|---|---|
Market Cap | $1.16B | $14.36B |
Volume | 3,176,523 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $185.50 |
52-Week Low | $20.66 | $123.10 |
Typical Hold Time | 61 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.06 with a 2.22% daily gain but maintains a bearish technical outlook. The ETF tracks Hong Kong equities, which face headwinds from Federal Reserve policy and US-Iran tensions, as the Hang Seng Index has declined over 11% from yearly highs. Moving averages signal strong bearish momentum while oscillators show neutral conditions, with key support at $21.
The outlook remains cautious given Hong Kong's sensitivity to US-China relations and Fed policy. Near-term performance hinges on geopolitical developments and Chinese economic data. Risks include continued institutional selling and Hang Seng volatility, but oversold conditions may attract contrarian buyers if tensions ease.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
